While the mechanisms by which E2 promotes metastasis remain to be fully elucidated, a promising therapeutic strategy may involve the use of estrogen‐depletion therapies including aromatase inhibitors, which are already FDA‐approved for the treatment of ER+ breast cancers. The gene discussed is CYP19A1; the disease is breast carcinoma.